Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

NCT02179151 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

108

Enrollment

INDUSTRY

Sponsor class

Stopped FDA Clinical Hold

Conditions

Prader-Willi Syndrome
Obesity

Interventions

DRUG: ZGN-440 for Injectable Suspension
DRUG: ZGN-440 Placebo for Injectable Suspension

Sponsor

Zafgen, Inc.